[Beta-HCG positive seminoma--incidence with special reference to tumor marker concentration in testicular venous blood].
The treatment of so-called "marker-positive" pure seminoma is still a controversial subject. We report on 32 cases of seminoma treated within 2 years. In these we measured beta-HCG and AFP in a cubital vein and in the spermatic cord veins. While 78% of the patients affected had elevated beta-HCG levels in the spermatic cord, in only 25% elevated beta-HCG levels were found in a cubital vein. This shows the markedly higher sensitivity of marker evaluation in spermatic cord veins. Furthermore, we conclude that seminoma generally produces beta-HCG and that therefore no change of the usual principles of therapy is required.
Mumperow
E
E
Urologische Abteilung, Bundeswehrkrankenhauses Hamburg.
Kressel
K
K
Hartmann
M
M
D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D006063:Chorionic Gonadotropin / Q000097:blood*; D018997:Chorionic Gonadotropin, beta Subunit, Human; D004407:Dysgerminoma / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010446:Peptide Fragments / Q000097:blood*; D011379:Prognosis; D013085:Spermatic Cord / Q000098:blood supply; D013736:Testicular Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D013737:Testis / Q000473:pathology; D014680:Veins
D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments
Das beta-HCG-positive Seminom--Häufigkeit unter besonderer Berücksichtigung der Markerkonzentration im Hodenvenenblut.